Evidence map›Paper›PMID 42657379›Full record

ArticleJournal of translational internal medicine2026

Outcomes of patients with hematological malignancies complicated with autoimmune diseases after allogeneic hematopoietic stem cell transplantation: A ten-year real-world study.

Qiusha Huang, Jin Wu, Haixia Fu, Peng Zhao, Zhuoyu An, Yun He, Xiaolu Zhu, Qi Chen, Fengrong Wang, Yuanyuan Zhang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Qiusha HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Jin WuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Haixia FuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Peng ZhaoPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Zhuoyu AnPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yun HePeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiaolu ZhuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Qi ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Fengrong WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yuanyuan ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiaodong MoPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Wei HanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Chenhua YanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Jingzhi WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Huan ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yuhong ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Tingting HanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Meng LvPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yao ChenPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Lanping XuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.ORCID https://orcid.org/0000-0003-0245-6792

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Patients with autoimmune diseases (ADs) are at an increased risk of developing hematological malignancies (HMs). While allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for HMs, the outcomes in patients with concomitant ADs and the effects of transplantation on autoimmune conditions remain poorly characterized. Methods: In this real-world study, we compared transplantation outcomes between 41 patients with HMs and preexisting ADs and 123 matched controls with HMs but without ADs. Results: A total of 65.8% of the patients with ADs had a disease duration of ≥ 3 years. All patients achieved hematological recovery. The AD group had a significantly higher incidence of chronic graft-versus-host disease (70.7% Conclusions: Our results suggest that allo-HSCT in patients with HMs and ADs is associated with survival outcomes that appear comparable to those in patients without ADs but also induces complete remission of AD in most patients.

Indexed as

allogeneic hematopoietic stem cell transplantationautoimmune diseaseshematological malignancies

Identifiers

PMID42657379
PMCPMC13509153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.